Current and emerging immunotherapeutic approaches to the treatment of multiple myeloma

Current and emerging immunotherapeutic approaches to the treatment of multiple myeloma

Multiple myeloma (MM) has a worldwide incidence of 1–5/100,000/year. Outcomes have improved significantly in recent years following incorporation of immunomodulatory drugs and proteasome inhibitors into standard-of-care regimes. MM is profoundly immunosuppressive, enabling immune evasion, proliferat...

Full description

Bibliographic Details
Main Authors: Dawn Swan, Kevin Lynch, Mark Gurney, Michael O’Dwyer
Format: Article
Language:English
Published: SAGE Publishing 2019-06-01
Series:Therapeutic Advances in Hematology
Online Access:https://doi.org/10.1177/2040620719854171
id doaj-1a6cc4df5d284ab28ab3d9c6a0b5528e
record_format Article
spelling doaj-1a6cc4df5d284ab28ab3d9c6a0b5528e2020-11-25T03:12:30ZengSAGE PublishingTherapeutic Advances in Hematology2040-62152019-06-011010.1177/2040620719854171Current and emerging immunotherapeutic approaches to the treatment of multiple myelomaDawn SwanKevin LynchMark GurneyMichael O’DwyerMultiple myeloma (MM) has a worldwide incidence of 1–5/100,000/year. Outcomes have improved significantly in recent years following incorporation of immunomodulatory drugs and proteasome inhibitors into standard-of-care regimes. MM is profoundly immunosuppressive, enabling immune evasion, proliferation and disease progression. The role of the immune system in MM is becoming increasingly characterized and understood, and numerous therapies are under development or in routine clinical use targeting these elements of MM pathogenesis. In this review we discuss the immunosuppressive effects of MM, then the therapies targeting these defects. Specifically, we review the monoclonal and bispecific antibodies, alongside adoptive cellular therapies currently under investigation.https://doi.org/10.1177/2040620719854171
collection DOAJ
language English
format Article
sources DOAJ
author Dawn Swan
Kevin Lynch
Mark Gurney
Michael O’Dwyer
spellingShingle Dawn Swan
Kevin Lynch
Mark Gurney
Michael O’Dwyer
Current and emerging immunotherapeutic approaches to the treatment of multiple myeloma
Therapeutic Advances in Hematology
author_facet Dawn Swan
Kevin Lynch
Mark Gurney
Michael O’Dwyer
author_sort Dawn Swan
title Current and emerging immunotherapeutic approaches to the treatment of multiple myeloma
title_short Current and emerging immunotherapeutic approaches to the treatment of multiple myeloma
title_full Current and emerging immunotherapeutic approaches to the treatment of multiple myeloma
title_fullStr Current and emerging immunotherapeutic approaches to the treatment of multiple myeloma
title_full_unstemmed Current and emerging immunotherapeutic approaches to the treatment of multiple myeloma
title_sort current and emerging immunotherapeutic approaches to the treatment of multiple myeloma
publisher SAGE Publishing
series Therapeutic Advances in Hematology
issn 2040-6215
publishDate 2019-06-01
description Multiple myeloma (MM) has a worldwide incidence of 1–5/100,000/year. Outcomes have improved significantly in recent years following incorporation of immunomodulatory drugs and proteasome inhibitors into standard-of-care regimes. MM is profoundly immunosuppressive, enabling immune evasion, proliferation and disease progression. The role of the immune system in MM is becoming increasingly characterized and understood, and numerous therapies are under development or in routine clinical use targeting these elements of MM pathogenesis. In this review we discuss the immunosuppressive effects of MM, then the therapies targeting these defects. Specifically, we review the monoclonal and bispecific antibodies, alongside adoptive cellular therapies currently under investigation.
url https://doi.org/10.1177/2040620719854171
work_keys_str_mv AT dawnswan currentandemergingimmunotherapeuticapproachestothetreatmentofmultiplemyeloma
AT kevinlynch currentandemergingimmunotherapeuticapproachestothetreatmentofmultiplemyeloma
AT markgurney currentandemergingimmunotherapeuticapproachestothetreatmentofmultiplemyeloma
AT michaelodwyer currentandemergingimmunotherapeuticapproachestothetreatmentofmultiplemyeloma
_version_ 1724650098146672640

Similar Items